Bill could make ‘magic mushrooms' a legal treatment option in New Mexico
SANTA FE, N.M. (KRQE) – So-called 'magic mushrooms' could soon be used to treat patients with certain medical conditions in New Mexico. Bipartisan bill SB 219 which would legalize psilocybin has been moving quickly through the legislative session.
Story continues below
DWI Scandal: Another BCSO deputy placed on leave in connection to DWI dismissals
Entertainment: Visit these 10 iconic film locations in New Mexico
Events: What's happening around New Mexico March 14-20
The bill is meant to help people suffering from conditions like PTSD and severe depression. Although the idea is controversial, on Monday it received a lot of support. 'This is another option, that's all this is. It's another option but New Mexicans deserve to have this option,' said Sen. Jeff Steinborn (D-Las Cruces).
Giving New Mexicans more ways to improve their health when other traditional medical treatments haven't worked, is what Sen. Steinborn said his bill to legalize psilocybin, the active ingredient in psychedelic mushrooms, is meant to do.
'We have New Mexicans who are suffering with various conditions that are really kind of end runs in some cases, major drug-resistant depression where the pharmaceutical world isn't giving them any relief or they have major major side effects, they need another option,' said Sen. Steinborn.
Modeled after programs in Oregon and Colorado, the bipartisan bill would allow the drug to be administered to a patient suffering from conditions including PTSD, severe depression, end-of-life anxiety, and addictions. Patients would be supervised and would only need the treatment once or twice.
Lawmakers emphasized this would be for use in medical settings only and would not create psilocybin dispensaries. Supporters spoke during the bill's last committee hearing on Monday.
'By creating a structured regulated program for psilocybin treatment, this bill ensures that patients in New Mexico can safely and legally access the miraculous benefits under medical supervision,' said Denali Wilson, supporter of the bill.
'My psychiatrist had me try psilocybin-assisted therapy, my depression is now completely cured and my life has been saved so I ask you to please support this bill,' said a supporter named Molly who underwent psilocybin treatment.
Some committee members expressed concerns about potential negative side effects but sponsors say the risks are low. 'It's a medicine of the mind in a way that has physical manifestations and sure it can be intense and a very very small amount of people could need extra deescalation or whatever from the experience, but by and large the outcome is very safe,' said Sen. Steinborn.
The bill passed 8-1 in committee. It now heads to the House floor. If it passes there, it will head to the governor's desk. There are only five days left of the legislative session.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 hours ago
- Miami Herald
VA Marks Benefits Milestone For Veterans
The Department of Veterans Affairs (VA) has announced that its mobile app has now accumulated more than 3 million downloads since its launch in 2021. The Health and Benefits app, which has 1.4 million active users, provides veterans access to information on health care and benefits. It allows users to refill and track VA prescriptions, review appointments, review claims and appeals status, submit evidence for claims and appeals, review VA payment and direct deposit information, locate the closest VA facilities, access the Veterans Crisis Line and show proof of Veteran status. VA Acting Assistant Secretary for Information and Technology and Acting Chief Information Officer Eddie Pool said: "VA's Health and Benefits app gives Veterans fast and convenient access to a host of important information, from appointments to prescriptions and benefits. We encourage all VA-enrolled Veterans to stay connected and informed by downloading the app." This story will be updated. Related Articles How Veteran's Benefits Are Impacted by Trump's Tax Bill: What to KnowHegseth Joins Veterans in Normandy to Mark 81st Anniversary of D-DayList of Cities Hosting 50501 Protests on June 6Harvey Milk Navy Ship To Be Renamed-Vets Call It 'Insult to LGBTQ Troops' 2025 NEWSWEEK DIGITAL LLC.
Yahoo
4 hours ago
- Yahoo
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized drug delivery technologies for surgical infection prevention. The below report explores the company's breakthrough PLEX platform technology, its upcoming topline phase 3 data, and potential implications for transforming surgical care practices in the multi-billion dollar surgical site infection prevention market. This report contains sponsored content, please see refer to the disclaimers and disclosures included at the end of this report. Executive Summary The surgical site infection (SSI) prevention landscape stands at a potential inflection point as PolyPid Ltd. prepares to announce topline results from its pivotal SHIELD II Phase 3 trial by the end of Q2 2025. The company's D-PLEX100 represents a paradigm shift in infection prevention, utilizing novel polymer-lipid encapsulation matrix (PLEX) technology to deliver sustained antibiotic release directly at surgical sites for 30 days. With SSIs affecting up to 30% of colorectal surgeries and imposing substantial healthcare costs estimated at $10 billion annually in the US and EU, successful development of D-PLEX100 could address a critical unmet medical need. The FDA's assignment of Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations underscores the regulatory recognition of this approach's potential Critical Challenge of Surgical Site Infections Surgical site infections remain one of healthcare's most persistent challenges, representing 20% of all healthcare-associated infections in US hospitals. Despite advances in surgical techniques and prophylactic protocols, SSI rates in high-risk procedures like colorectal surgery can reach 30%, leading to extended hospital stays of 7-11 additional days and mortality risk increases of 2-11 fold. The economic burden is staggering, with direct costs averaging $11,000-26,000 per infection and total annual costs reaching approximately $10 billion in the US alone. Current prevention strategies rely primarily on systemic antibiotic prophylaxis administered intravenously 30-60 minutes before surgery. However, this approach faces fundamental limitations. Surgical incisions disrupt local blood flow, significantly limiting antibiotic penetration to the precise site where infections occur. Moreover, systemic administration exposes patients to higher drug concentrations throughout the body, potentially increasing toxicity risks and contributing to antimicrobial resistance development. PLEX Technology: A Novel Approach to Localized Drug Delivery PolyPid's proprietary PLEX technology represents a sophisticated advancement in controlled drug delivery systems. The platform creates thousands of alternating layers of biocompatible polymers and lipids that physically embed active pharmaceutical ingredients. As these outer layers gradually disintegrate upon exposure to body fluids, they enable precise, predetermined drug release rates spanning several days to months. For D-PLEX100, this technology pairs with doxycycline, a broad-spectrum antibiotic effective against both gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. The formulation achieves local antibiotic concentrations 10-115 times higher than systemic administration while using only a fraction of the total drug amount, potentially minimizing systemic exposure and associated side effects. Clinical Development Progress and Regulatory Recognition The clinical development program for D-PLEX100 has demonstrated encouraging signals across multiple surgical contexts. In Phase 2 abdominal surgery trials, D-PLEX100 plus standard of care achieved a statistically significant 59% reduction in the primary endpoint compared to standard of care alone (p=0.0086). Perhaps more notably, the treatment group experienced zero deaths compared to five in the control arm within 60 days post-surgery. The pivotal SHIELD I Phase 3 trial, while not meeting its primary endpoint in the full intent-to-treat population, revealed compelling efficacy in a pre-specified subgroup analysis. Among patients with large surgical incisions (>20 cm), D-PLEX100 demonstrated a statistically significant 54% reduction in the composite primary endpoint of SSIs, reinterventions, and mortality (p=0.0032). This finding directly informed the design of the ongoing SHIELD II trial, which focuses specifically on this higher-risk patient FDA's regulatory designations reflect recognition of D-PLEX100's potential significance. Breakthrough Therapy designation is reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions. Fast Track designation facilitates more frequent FDA communications and potentially accelerated review timelines. The QIDP designation provides additional market exclusivity incentives for addressing antimicrobial resistance challenges. SHIELD II: A Potentially Definitive Study The ongoing SHIELD II Phase 3 trial represents a carefully designed study incorporating lessons learned from SHIELD I. Following an independent Data Safety Monitoring Board's review of unblinded efficacy data from the first 430 enrolled patients, the board recommended concluding the study at 800 patients—the lowest sample size reassessment option available. This recommendation, while requiring additional enrollment beyond the initially planned 624 patients, may suggest positive efficacy trends in the analyzed interim data. The study's multinational design spans approximately 60 centers across the United States, Europe, and Israel, enhancing the generalizability of results across different healthcare settings and patient populations. The primary endpoint focuses on a composite of SSI events, reinterventions, and mortality within 30 days post-surgery, as adjudicated by an independent committee. Broader Industry ImplicationsSuccess of D-PLEX100 could catalyze broader adoption of localized drug delivery approaches in surgical settings. The technology's platform nature suggests potential applications beyond infection prevention, including localized chemotherapy delivery through the company's OncoPLEX program, currently in preclinical development for solid tumor treatment. The substantial market opportunity—with approximately 12 million eligible procedures annually in the US and 8 million in Europe—underscores the potential healthcare impact. PolyPid has already secured European commercialization rights through a partnership with Advanz Pharma, valued at up to $115 million plus royalties, while advancing discussions for US market partnerships. Conclusion As the pharmaceutical industry grapples with antimicrobial resistance and healthcare systems seek cost-effective solutions to persistent clinical challenges, D-PLEX100's approaching data readout represents a potentially significant milestone. The convergence of compelling preclinical and early clinical data, regulatory recognition, and substantial unmet medical need positions this development as one to monitor closely in the evolving landscape of surgical infection News Highlight from PolyPid: PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections >> Click here to Subscribe for more updates like this or go to * Legal Disclaimer & Disclosure: Nothing in this report constitutes medical, financial or any form professional or licensedadvice. This report is published by 'PESG Research', a digital promotional content brand who's operators are compensated to provide digestable and favorabel coverage of companies. This report contains and is a form of paid promotional content or advertising for PolyPid Ltd and was produced as part of the fee's they pay PESG's operators, Arx Advisory Ltd. This report has not been reviewed or approved by PolyPId prior to publication and it does not represent an official communication from PolyPid. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from PolyPid as part of an ongoing agreement starting May 1, 2025 in return for distribution and promotional coverage services, and receive additional monthly compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective.
Yahoo
4 hours ago
- Yahoo
Karoline Leavitt Squirms Over Maria Bartiromo's Blunt Question About Elon Musk
White House press secretary Karoline Leavitt on Sunday tried to laugh off Fox News host Maria Bartiromo's question about an alleged physical altercation that reportedly erupted between top Trump ally-turned-detractor Elon Musk and Treasury Secretary Scott Bessent. Citing a news report from The Washington Post that now-departed Department of Government Efficiency boss Musk body-checked Bessent during a blowout over a difference in opinion at the White House in April, Bartiromo said: 'We're all trying to figure out what happened here and how come this got to this level.' She then asked Leavitt, 'What happened? Did he body-check the treasury secretary in the White House?' Leavitt chuckled and tried to spin the clash as one of the 'healthy disagreements amongst the Cabinet and Elon Musk' that she claimed only 'really speaks to the heart of this Cabinet and the president's team, that they can have these robust disagreements and then still come together to do what's right for the people they are serving.' Bartiromo pressed later, 'What I'm trying to understand here is how rough this got, because the president said that Elon Musk disrespected the office of the president.' 'Now, we know that there was real disrespect in a lot of those X posts from Elon Musk, for sure. But did he actually get physical?' she continued. 'Was there a fistfight that he body-checked the treasury secretary?' 'I certainly wouldn't describe it as a fistfight, Maria,' Leavitt responded. 'It was definitely a disagreement. Although, I was not there, I didn't witness it with my own eyes. I heard about it through secondhand reporting. But again, we've moved on from that. The president has moved on from it.' Watch here: Marjorie Taylor Greene's 'Lesson For Us All' Leaves Seth Meyers Absolutely Floored 6 Wildly Different Ways Fox News Hosts Struggled To Process Trump-Musk Blowup German Leader Politely Shuts Down Trump's Hot Take On D-Day 1 Subtle Barb In Trump-Musk Blow-Out Has Dana Bash Saying 'Wow, Wow, Wow'
